Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years

Abstract: Cancer is one of the primary causes of mortality worldwide. Despite nowadays are numerous therapeutic treatments to fight tumor progression, it is still challenging to completely overcome it. It is known that Histone Deacetylases (HDACs), epigenetic enzymes that remove acetyl groups from lysines on histone's tails, are overexpressed in various types of cancer, and their inhibition represents a valid therapeutic strategy. To date, some HDAC inhibitors have achieved FDA approval. Nevertheless, several other potential drug candidates have been developed. This review aims primarily to be comprehensive of the studies done so far regarding HDAC inhibitors bearing heterocyclic rings since their therapeutic potential is well known and has gained increasing interest in recent years. Hence, inserting heterocyclic moieties in the HDAC‐inhibiting scaffold can be a valuable strategy to provide potent and/or selective compounds. Here, in addition to summarizing the properties of novel heterocyclic HDAC inhibiting compounds, we also provide ideas for developing new, more potent, and selective compounds for treating cancer.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: Heterocycles–Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years ; day:29 ; month:08 ; year:2024 ; extent:54 ; ChemMedChem ; (29.08.2024) (gesamt 54)

Contributors, Places and Time

• Creator: Raucci, Alessia ; Castiello, Carola ; Mai, Antonello ; Zwergel, Clemens ; Valente, Sergio

Further information

• DOI: 10.1002/cmdc.202400194
• URN: urn:nbn:de:101:1-2408301409247.854849770144
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:37 AM CEST